VAXXINITY INC-A (VAXX) Stock Price & Overview
NASDAQ:VAXX • US92244V1044
Current stock price
The current stock price of VAXX is 0.1111 USD. Today VAXX is down by -15.26%. In the past month the price decreased by -81.79%. In the past year, price decreased by -94.42%.
VAXX Key Statistics
- Market Cap
- 14.082M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.45
- Dividend Yield
- N/A
VAXX Stock Performance
VAXX Stock Chart
VAXX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VAXX. When comparing the yearly performance of all stocks, VAXX is a bad performer in the overall market: 99.91% of all stocks are doing better.
VAXX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VAXX. Both the profitability and financial health of VAXX have multiple concerns.
VAXX Earnings
VAXX Forecast & Estimates
8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.
VAXX Groups
Sector & Classification
VAXX Financial Highlights
Over the last trailing twelve months VAXX reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 25.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -128.51% | ||
| ROE | -424.66% | ||
| Debt/Equity | 0.99 |
VAXX Ownership
VAXX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 368.645B | ||
| AMGN | AMGEN INC | 15.25 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.68 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.84 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 11.2 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.55 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VAXX
Company Profile
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 87 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.
Company Info
IPO: 2021-11-11
VAXXINITY INC-A
1717 Main Street, Suite 3388
Dallas TEXAS US
Employees: 87
Phone: 12542445739
VAXXINITY INC-A / VAXX FAQ
Can you describe the business of VAXXINITY INC-A?
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 87 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.
What is the stock price of VAXXINITY INC-A today?
The current stock price of VAXX is 0.1111 USD. The price decreased by -15.26% in the last trading session.
What is the dividend status of VAXXINITY INC-A?
VAXX does not pay a dividend.
What is the ChartMill rating of VAXXINITY INC-A stock?
VAXX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy VAXX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VAXX.
What is the outstanding short interest for VAXXINITY INC-A?
The outstanding short interest for VAXXINITY INC-A (VAXX) is 0.31% of its float.